Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP19A1 | P11511 | 1/20 | 0.38 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.36 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.31 |
| ▸ | FAAH | O00519 | 1/20 | 0.31 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21370103 | 0.83 | CYP19A1 (0.39) | CYP19A1CYP2D6HSP90AA1CYP3A4FAAH | |
| SCHEMBL15979319 | 0.80 | CYP19A1 (0.37) | CYP19A1CYP2D6HSP90AA1CYP3A4FAAH | |
| SCHEMBL22365189 | 0.77 | CYP19A1 (0.35) | CYP19A1CYP2D6HSP90AA1 | |
| SCHEMBL23842514 | 0.76 | CYP2D6 (0.41) | CYP19A1CYP2D6HSP90AA1CYP3A4FAAH | |
| SCHEMBL22585255 | 0.76 | CYP2D6 (0.41) | CYP19A1CYP2D6HSP90AA1CYP3A4FAAH | |
| SCHEMBL21784451 | 0.75 | CYP2D6 (0.41) | CYP19A1CYP2D6HSP90AA1CYP3A4FAAH | |
| SCHEMBL18415044 | 0.75 | FAAH (0.38) | CYP19A1CYP2D6CYP3A4FAAH | |
| SCHEMBL24137127 | 0.75 | CYP19A1 (0.41) | CYP19A1HSP90AA1CYP3A4 | |
| SCHEMBL23842473 | 0.75 | CYP19A1 (0.41) | CYP19A1CYP2D6HSP90AA1CYP3A4P2RX7 | |
| SCHEMBL16677128 | 0.75 | CYP19A1 (0.41) | CYP19A1CYP2D6HSP90AA1CYP3A4P2RX7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2019178191-A1 | O-GLYCOPROTEIN-2-ACETAMIDO-2-DEOXY-3-D-GLYCOPYRANOSIDASE INHIBITORS | BIOGEN MA INC. (US) | 2019-09-19 | — | — | WO | disclosed |